Atossa Therapeutics Inc

Atossa Therapeutics insider buys signal confidence amid volatile market; tech‑driven (Z‑endoxifen) trials, payer strategy, and AI adoption shape future value.

Atossa insiders buy 40,000 shares ahead of May 19 data—signaling confidence that a new SERM could unlock value for a 64% discounted stock.

CEO Steven Quay’s bulk Atossa Therapeutics RSU purchase signals confidence as insiders boost long‑term stakes amid a 52‑week low, hinting at upside potential.

Atossa Therapeutics insider buys and stock‑option grants signal confidence; the firm’s antibody therapies (ATC‑201, ATC‑305) show early promise, fast‑track FDA status, and potential upside despite current price volatility.